http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006013049-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54a9f4f0e604e5a602af9b4850fe216a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1805b648af8ef3186663b7d1da20224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_776d15fc644e6564a096fa20cd708502
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04
filingDate 2005-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2d4d08e02fa9dec995c33040480a2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6704d5210e965f68cebd7e9e04d2de6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_231cd696a2bb7957af9f3d089e80eb3b
publicationDate 2006-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006013049-A3
titleOfInvention Benzyloxy derivatives as maob inhibitors
abstract The present invention relates to compounds of the general formula (I); wherein Rl is halogen; R2 is -C(O)NH2,-C(NH2)=N-OH, -C(O)CH2Br, -C(O)N(CH3)OCH3 or-C(O)-lower alkyl, or is a 5-membered heteroaryl group, containing 2 or 3 heteroatoms, selected from the group consisting of N, O or S, optionally substituted by R3, wherein R3 is lower alkyl, -NR'R' or -C(O)R; R is NR'R', lower alkyl, or lower alkoxy; R'/R' are independently hydrogen or lower alkyl; as well as their pharmaceutically acceptable salts for the treatment of diseases, which are mediated by monoamine oxidase B inhibitors, for example Alzheimer's disease and senile dementia.
priorityDate 2004-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004026826-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004026827-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394843

Total number of triples: 36.